[A23-129] Lebrikizumab (atopic dermatitis) – Benefit assessment according to §35a Social Code Book V
Last updated 15.03.2024
Project no.:
A23-129
Commission:
Commission awarded on 11.12.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Skin and hair
Adults and adolescents 12 years and older with moderate to severe atopic dermatitis who are candidates for systemic therapy
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A23-129_en